Literature DB >> 22108047

Proteomic analysis of amniotic fluid of pregnant rats with spina bifida aperta.

Liping Shan1, Yang Fan, Hui Li, Wei Liu, Hui Gu, Fenghua Zhou, Zhengwei Yuan.   

Abstract

Congenital spina bifida aperta is a common congenital malformation in children and has an incidence of 1‰ to 5‰ in China. However, we currently lack specific biomarkers for screening or prenatal diagnosis and there is no method to entirely cure or prevent such defects. In this study, we used two-dimensional gel electrophoresis (2-DE)/mass spectrometry (MS) to characterize differentially expressed proteins in amniotic-fluid samples (AFSs) of embryonic day (E) 17.5 rat fetuses with spina bifida aperta induced by retinoic acid (RA). We identified five proteins differentially expressed in AFSs of spina bifida aperta, including three upregulated proteins (transferrin, alpha-1 antiproteinase and signal recognition particle receptor, B subunit [SRPRB] 55 kDa), two downregulated proteins (apolipoprotein A IV [APO A4] and Srprb 77 kDa). Specifically, we found 11 alpha-1 fetoprotein (AFP) fragments that were downregulated and 35 AFP fragments that were upregulated in AFSs from embryos with spina bifida aperta. Of the downregulated AFP fragments, 72.7% (8/11) were confined to the AFP N-terminus (amino acids [aas] 25-440) and 77.1% (27/35) of upregulated AFP fragments were confined to the AFP C-terminus (aas 340-596). We also confirmed APO A4 and AFP by immunoblot analysis. This is the first comparative proteomic study of AFSs from rat fetuses with spina bifida aperta. We demonstrate proteomic alterations in the AFS of spina bifida aperta, which may provide new insights in neural tube defects and contribute to the prenatal screening.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108047     DOI: 10.1016/j.jprot.2011.10.033

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  7 in total

1.  Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis.

Authors:  Zhen Guan; Yingchao Liang; Xiuwei Wang; Zhiqiang Zhu; Aiyun Yang; Shen Li; Jialu Yu; Bo Niu; Jianhua Wang
Journal:  Neurochem Res       Date:  2022-08-12       Impact factor: 4.414

Review 2.  Neural tube defects: from a proteomic standpoint.

Authors:  Tania M Puvirajesinghe; Jean-Paul Borg
Journal:  Metabolites       Date:  2015-03-17

3.  Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects.

Authors:  Lizhu Chen; Hui Gu; Jun Li; Ze-Yu Yang; Xiao Sun; Li Zhang; Liping Shan; Lina Wu; Xiaowei Wei; Yili Zhao; Wei Ma; Henan Zhang; Songying Cao; Tianchu Huang; Jianing Miao; Zhengwei Yuan
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

4.  Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.

Authors:  Dong An; Xiaowei Wei; Hui Li; Hui Gu; Tianchu Huang; Guifeng Zhao; Bo Liu; Weilin Wang; Lizhu Chen; Wei Ma; Henan Zhang; Songying Cao; Zhengwei Yuan
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

5.  Key Modules and Hub Genes Identified by Coexpression Network Analysis for Revealing Novel Biomarkers for Spina Bifida.

Authors:  Zijian Li; Juan Feng; Zhengwei Yuan
Journal:  Front Genet       Date:  2020-12-02       Impact factor: 4.599

6.  Serum exosomal coronin 1A and dynamin 2 as neural tube defect biomarkers.

Authors:  Yanfu Wang; Ling Ma; Shanshan Jia; Dan Liu; Hui Gu; Xiaowei Wei; Wei Ma; Wenting Luo; Yuzuo Bai; Weilin Wang; Zhengwei Yuan
Journal:  J Mol Med (Berl)       Date:  2022-08-01       Impact factor: 5.606

7.  SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.

Authors:  Zhenjiang Liu; Zhengwei Yuan; Qun Zhao
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.